Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HURA NASDAQ:PROK NASDAQ:PRTA NASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHURATuHURA Biosciences$2.51$2.13$0.41▼$4.05$159.84M-0.01865,704 shs340,301 shsPROKProKidney$1.71-2.3%$1.97$0.54▼$7.13$528.35M1.7693,336 shs1.11 million shsPRTAProthena$9.86+2.7%$10.01$4.32▼$11.80$502.59M-0.23455,241 shs452,435 shsTRDAEntrada Therapeutics$6.83-6.7%$12.31$4.93▼$16.45$284.17M-0.09587,334 shs779,089 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHURATuHURA Biosciences0.00%+4.58%-20.32%+88.72%-35.48%PROKProKidney-2.29%-9.04%-10.47%-13.64%+121.76%PRTAProthena+2.71%-7.35%-7.07%+10.04%+43.11%TRDAEntrada Therapeutics-6.69%-0.29%-51.32%-37.22%-14.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHURATuHURA Biosciences$2.51$2.13$0.41▼$4.05$159.84M-0.01865,704 shs340,301 shsPROKProKidney$1.71-2.3%$1.97$0.54▼$7.13$528.35M1.7693,336 shs1.11 million shsPRTAProthena$9.86+2.7%$10.01$4.32▼$11.80$502.59M-0.23455,241 shs452,435 shsTRDAEntrada Therapeutics$6.83-6.7%$12.31$4.93▼$16.45$284.17M-0.09587,334 shs779,089 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHURATuHURA Biosciences0.00%+4.58%-20.32%+88.72%-35.48%PROKProKidney-2.29%-9.04%-10.47%-13.64%+121.76%PRTAProthena+2.71%-7.35%-7.07%+10.04%+43.11%TRDAEntrada Therapeutics-6.69%-0.29%-51.32%-37.22%-14.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHURATuHURA Biosciences 2.67Moderate Buy$9.00258.57% UpsidePROKProKidney 2.50Moderate Buy$7.40332.75% UpsidePRTAProthena 2.36Hold$21.78120.87% UpsideTRDAEntrada Therapeutics 2.50Moderate Buy$18.25167.20% UpsideCurrent Analyst Ratings BreakdownLatest HURA, PROK, PRTA, and TRDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026TRDAEntrada Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.005/8/2026TRDAEntrada Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/8/2026PRTAProthena CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026PRTAProthena Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$19.00 ➝ $20.004/27/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026HURATuHURA Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/27/2026HURATuHURA Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/21/2026HURATuHURA Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PROKProKidney Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026HURATuHURA Biosciences Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/6/2026TRDAEntrada Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$21.00 ➝ $23.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/APROKProKidney$890K580.09N/AN/A($3.36) per share-0.51PRTAProthena$9.68M53.32N/AN/A$5.97 per share1.65TRDAEntrada Therapeutics$25.42M10.43N/AN/A$6.98 per share0.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHURATuHURA Biosciences-$30.05M-$0.63N/AN/AN/AN/A-182.40%-117.49%5/15/2026 (Estimated)PROKProKidney-$68.99M-$0.52N/AN/AN/A-7,725.20%N/A-18.83%N/APRTAProthena-$244.09M-$2.82N/AN/A1.54-260.92%-43.44%-36.87%8/3/2026 (Estimated)TRDAEntrada Therapeutics-$143.75M-$3.99N/AN/AN/A-2,895.05%-51.22%-42.20%N/ALatest HURA, PROK, PRTA, and TRDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026N/AHURATuHURA Biosciences-$0.12N/AN/AN/AN/AN/A5/7/2026Q1 2026PRTAProthena-$0.31$0.60+$0.91$0.60$0.81 million$51.08 million5/7/2026Q1 2026TRDAEntrada Therapeutics-$1.06-$0.95+$0.11-$0.95$2.92 million$0.88 million3/31/2026Q4 2025HURATuHURA Biosciences-$0.1233-$0.13-$0.0067-$0.10N/AN/A3/18/2026Q4 2025PROKProKidney-$0.16-$0.14+$0.02-$0.13$0.00 million$0.23 million2/26/2026Q4 2025TRDAEntrada Therapeutics-$1.32-$0.94+$0.38-$0.94$7.41 million$1.30 million2/19/2026Q4 2025PRTAProthena-$0.45-$0.44+$0.01-$0.40$0.67 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHURATuHURA BiosciencesN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHURATuHURA BiosciencesN/A0.780.78PROKProKidneyN/A9.139.13PRTAProthenaN/A10.4310.43TRDAEntrada TherapeuticsN/A13.9012.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHURATuHURA Biosciences0.62%PROKProKidney51.59%PRTAProthena97.08%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipHURATuHURA Biosciences0.20%PROKProKidney39.83%PRTAProthena10.40%TRDAEntrada Therapeutics9.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHURATuHURA BiosciencesN/A63.68 million63.56 millionN/APROKProKidney3301.92 million181.66 millionOptionablePRTAProthena13052.35 million46.91 millionOptionableTRDAEntrada Therapeutics11038.82 million35.14 millionOptionableHURA, PROK, PRTA, and TRDA HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 14 at 10:30 PM | prnewswire.comHC Wainwright Has Positive Estimate for TRDA Q2 EarningsMay 12 at 7:39 AM | marketbeat.comEntrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 11, 2026 | globenewswire.comCritical Survey: ABVC BioPharma (NASDAQ:ABVC) vs. Entrada Therapeutics (NASDAQ:TRDA)May 11, 2026 | americanbankingnews.comHC Wainwright & Co. downgrades Entrada Therapeutics (TRDA)May 9, 2026 | msn.comEntrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety ProfileMay 9, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Beam Therapeutics (BEAM)May 9, 2026 | theglobeandmail.comEntrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Expectations By $0.11 EPSMay 7, 2026 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), Edgewise Therapeutics (EWTX) and Elevance Health (ELV)May 7, 2026 | theglobeandmail.comEntrada plunges after early-stage trial data for Duchenne therapyMay 7, 2026 | msn.comEntrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's WhyMay 7, 2026 | benzinga.comEntrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comEntrada Therapeutics (NASDAQ:TRDA) Reaches New 12-Month High on Earnings BeatMay 7, 2026 | marketbeat.comEntrada Therapeutics Reports Positive Topline Results from ELEVATE-44-201 Study in Duchenne Muscular Dystrophy and Updates on Clinical Pipeline and Financial PositionMay 7, 2026 | quiverquant.comQEntrada Therapeutics Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comEntrada's Duchenne drug shown to improve muscle function in early trialMay 7, 2026 | reuters.comEntrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 StudyMay 7, 2026 | globenewswire.comEntrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on ...May 6, 2026 | markets.businessinsider.comEntrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026May 6, 2026 | globenewswire.comEntrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?May 5, 2026 | zacks.comEntrada Therapeutics (NASDAQ:TRDA) COO Sells $229,950.00 in StockMay 5, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHURA, PROK, PRTA, and TRDA Company DescriptionsTuHURA Biosciences NASDAQ:HURA$2.51 0.00 (0.00%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.49 -0.02 (-0.80%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.ProKidney NASDAQ:PROK$1.71 -0.04 (-2.29%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.74 +0.03 (+1.46%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Prothena NASDAQ:PRTA$9.86 +0.26 (+2.71%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$9.86 0.00 (-0.05%) As of 05/14/2026 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Entrada Therapeutics NASDAQ:TRDA$6.83 -0.49 (-6.69%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$6.66 -0.17 (-2.47%) As of 04:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
